[CAS NO. 92478-27-8] Morinidazole
PRODUCTS SPECIFICATIONS [92478-27-8]
DESCRIPTION [92478-27-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 270.29 |
| Molecular Formula | C11H18N4O4 |
| SMILES | OC(CN1C([N+]([O-])=O)=CN=C1C)CN2CCOCC2 |
Summary
Morinidazole is an orally active and 5-nitroimidazole antimicrobial agent that undergoes extensive metabolism in humans via N + -glucuronidation and sulfation. Morinidazole can be used for bacterial infections research including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria [1] .
IC50 & Target
organic anion transporter [1]
In Vitro
Morinidazole can be metabolized to N
+
-glucuronide of S-morinidazole [M8-1] and N
+
-glucuronide of R-morinidazole [M8-2] via N
+
-glucuronidation, and sulfate conjugate of morinidazole [M7] via sulfation
[1]
.
M7 is a substrate for organic anion transporter 1 (OAT1) and OAT3 (K
m
=28.6 and 54.0 μM, respectively), M8-1 and M8-2 are the substrates for OAT3
[1]
.
Morinidazole shows activity against
Trichomonas vaginalis
and
Entamoeba histolytica
in vitro, with MIC values of 2 μg/mL and 3 μg/mL, respectively
[2]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Morinidazole (20 mg/kg or 25 mg/kg; p.o.; single dose) inhibits
Trichomonas vaginalis
and
Entamoeba histolytica
in vivo in rats with EC
50
s of 20 mg/kg and 25 mg/kg, respectively
[2]
.
Morinidazole (50 mg/kg; i.v.; 0.25, 0.75, 1.5 h) shows a different concentration in tissues after intravenous injection, with a higher concentration in liver, kidney, plasma than lung, heart, and spleen in mice
[3]
.
Pharmacokinetic parameters of Morinidazole in control and 5/6 nephrectomized (Nx) rats
[3]
| Group | C max (μg/mL) | T max (h) | T 1/2 (h) | AUC 0-t (μg·h/mL) | AUC 0-∞ (μg·h/mL) | CL (mL/h/kg) | V ss (mL/kg) | MRT (h) |
| Control rats | 48.2 | 0.08 | 1.16 | 87.2 | 87.3 | 582 | 805 | 1.39 |
| 5/6 Nx rats | 53.2 | 0.08 | 1.32 | 91.2 | 91.3 | 552 | 891 | 1.62 |
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Renal failure model in SD rats (180-220 g) [3] |
| Dosage: | 50 mg/kg |
| Administration: | Intravenous injection; sacrificed rats at 0.25, 0.75, and 1.50 hours after dose administration |
| Result: | Increased plasma exposures slightly compared with control. |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT03391440 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Pelvic Inflammatory Disease
|
September 2016 | Phase 4 |
| NCT03380793 | Jiangsu Hansoh Pharmaceutical Co., Ltd. |
Appendicitis
|
September 2016 | Phase 4 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : ≥ 100 mg/mL ( 369.97 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 3.6997 mL | 18.4986 mL | 36.9973 mL |
| 5 mM | 0.7399 mL | 3.6997 mL | 7.3995 mL |
| 10 mM | 0.3700 mL | 1.8499 mL | 3.6997 mL |
References
- [1] Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearanceof the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61.
- [2] Kong F, et al. Increased Plasma Exposures of Conjugated Metabolites of Morinidazole in Renal Failure Patients: A Critical Role of Uremic Toxins. Drug Metab Dispos. 2017 Jun;45(6):593-603.
- [3] Lu Aifeng, et al. Application of α-(morpholine-1-yl)methyl-2-methyl-nitroimidazole-1-ethanol as anti-trichomonal agent and amebacide: China, CN1981764[P]. 2007-06-20.